New Hampshire
Baseline Needs
Assessment
Practitioners and Community
Stakeholders

Prepared by the UVM Center on Rural Addiction
Surveillance & Evaluation Core
February 2022

UVMCORA.ORG

NEW HAMPSHIRE: PRACTITIONERS AND STAKEHOLDERS

Contents
Executive Summary........................................................................................................................... 3
Practitioners ................................................................................................................................................ 5
Community Stakeholders ............................................................................................................................ 6

Rural County Location....................................................................................................................... 6
Practitioners ................................................................................................................................................ 6
Community Stakeholders ............................................................................................................................ 7

Work Setting and Role ...................................................................................................................... 8
Practitioners ................................................................................................................................................ 8
Community Stakeholders .......................................................................................................................... 10

Practitioner Waiver and Ability to Treat OUD ................................................................................ 11
Practitioner Difficulty Retaining Patients ....................................................................................... 12
Practitioner Concern about Treatment Adherence ........................................................................ 13
Number of Patients: Total and OUD Treatment ............................................................................. 14
Concern about Substances ............................................................................................................. 15
Practitioners .............................................................................................................................................. 15
Community Stakeholders .......................................................................................................................... 18

Practitioner Comfort Treating SUD ................................................................................................. 21
Training and Supports ..................................................................................................................... 27
Treatment Barriers.......................................................................................................................... 29
Practitioners .............................................................................................................................................. 29
Community Stakeholders .......................................................................................................................... 37

Beliefs.............................................................................................................................................. 39
COVID-19 Impact ............................................................................................................................ 56
Practitioner UVM CORA Resource Requests .................................................................................. 62
Practitioner Ability to Provide Data for Evaluation Efforts............................................................. 66
Most Important Improvement Needed .......................................................................................... 68
Share and Learn .............................................................................................................................. 68
Acknowledgements ........................................................................................................................ 69
Questions ........................................................................................................................................ 69
Suggested Reference ...................................................................................................................... 69

PAGE 2

UVMCORA.ORG

NEW HAMPSHIRE: PRACTITIONERS AND STAKEHOLDERS

Executive Summary
The mission of the University of Vermont Center on Rural Addiction (UVM CORA) is to expand
addiction treatment capacity in rural counties by providing consultation, resources, training, and
evidence-based technical assistance to healthcare practitioners and other staff. With our baseline
needs assessment, we aim to identify current and future addiction treatment needs and barriers in
New Hampshire with direct input from practitioners, policymakers, and other stakeholders. The
online survey was conducted from October 2020 to March 2021. This report includes responses from
practitioners and community stakeholders working in all counties in New Hampshire, highlighting
rural counties designated by the Health Resources & Services Administration (HRSA). Throughout
the report, we compare practitioner responses by rural and non-rural work location, as well as by
role type (i.e., counselors compared to clinicians), and buprenorphine waiver status of practitioners
who can prescribe medication (i.e., waivered practitioners compared to non-waivered practitioners).
We present the latter two comparisons both statewide and among rural practitioners only.
Our respondents included 152 practitioners and 101 community stakeholders working in New
Hampshire. Among practitioners, defined as working in a field where they may provide direct care
to persons with opioid use disorder (OUD), nearly half of respondents worked in counseling roles
(e.g., counselors, case managers, social workers; 47%). The remainder of practitioners worked in
clinical roles (53%), including nurse practitioners (18%), primary care practitioners (i.e., MD, DO)
(13%), and nurses (12%). Among community stakeholders, defined as working in a field where they
interact with or provide services to persons with OUD through work in the community, respondents
worked in a wide variety of settings including family resource centers/family support (19%), recovery
centers/recovery community organizations (13%), public health (13%), and community mental
health (7%).
Survey topics included concerns about substance use, comfort treating patients with substance use
disorder (SUD), training and support needs, provider and patient barriers to treatment, beliefs about
SUD and treatment, impacts of COVID-19, and the UVM CORA resources which may be of interest
and assistance to practitioners.
When asked about their concerns regarding substance use among their patients, practitioners’
greatest concerns were related to fentanyl, methamphetamine, and opioids in combination with
alcohol, stimulants, and sedatives. When asked about their concerns regarding substance use in their
community, community stakeholders were most concerned about fentanyl, heroin, methamphetamine, and opioids in combination with alcohol, stimulants, and sedatives.
Practitioners overwhelmingly endorsed lack of time, transportation, and other supports as a top
barrier to their patients receiving treatment for opioid use disorder (OUD). Community stakeholders
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similarly selected lack of time, transportation, and childcare access as a key challenge to patients
receiving treatment for OUD. Stakeholders also reported stigma, insufficient treatment capacity, and
lack of care coordination as top patient barriers.
Practitioners in New Hampshire reported a moderate level of comfort in treating patients with OUD
and treating special populations (i.e., families, adolescents, and pregnant patients) for SUDs.
Frequently requested UVM CORA resources included support and training for treating vulnerable
populations and training for addressing conditions co-occurring with SUDs.
When asked about their beliefs, two thirds of practitioners (65%) agreed or strongly agreed with the
statement, “Medications (like methadone and buprenorphine) are the most effective way to treat
people with opioid use disorder,” with seven percent disagreeing or strongly disagreeing. A
significantly greater proportion of practitioners in clinical roles (81%) agreed with the statement
compared to those in counseling roles (48%).
Given that our New Hampshire baseline needs assessment was conducted concurrently with the
COVID-19 pandemic, we also included several questions on the impact of the pandemic on substance
use and treatment availability. Substantial proportions of practitioners and community stakeholders
believed that substance use (practitioners: 77%; community stakeholders: 79%) and opioid use
(practitioners: 67%; community stakeholders: 57%) had increased in their communities since the
start of the COVID-19 pandemic. In contrast, very few practitioners (6%) and community
stakeholders (5%) believed that access to medications for OUD (MOUD) had increased.
Visit uvmcora.org to find more information about our baseline needs assessments in Vermont,
Maine, New Hampshire, and New York, as well as available resources and technical assistance on
substance use treatment.

Abbreviations Used Throughout This Report
UVM CORA: University of Vermont Center on Rural Addiction
OUD: Opioid use disorder
SUD: Substance use disorder
MOUD: Medications for opioid use disorder
HRSA: Health Resources and Services Administration
RCO: Recovery Community Organization

This publication is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and
Human Services (HHS) as part of an award totaling $13,699,254 with zero percentage financed with non-governmental sources. The
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HRSA,
U.S. Government.
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Responses and Inclusion Criteria
Practitioners and community stakeholders working across New Hampshire, from HRSA-designated
rural counties as well as non-rural counties1 (Figure 1), responded to our baseline needs assessment
survey. The online survey was conducted from October 2020 to March 2021. We began by sending
a contact survey link to practitioners and community stakeholders via email listservs, mailers, and
social media. Contacts whom we validated as being practitioners or community stakeholders
working in New Hampshire were invited to complete the
corresponding full survey (i.e., practitioner survey or
community stakeholder survey). Our partners at the University of New Hampshire Institute for Health Policy and
Practice’s New Hampshire Citizens Health Initiative
conducted additional outreach with these invitees,
including regular email outreach, to maximize the response
rate. After exclusions (further described in the sections
below), we received valid survey responses from 152
practitioners and 101 community stakeholders.
This report includes responses from practitioners and
community stakeholders working in all counties in New
Hampshire. Throughout the report, we compare
practitioner responses by work location (i.e., rural
Figure 1. Map of HRSA-designated rural
compared to non-rural), as well as by role type (i.e.,
counties (green) and non-rural counties (grey)
practitioners in counseling roles compared to practitioners
in New Hampshire.
in clinical roles), and buprenorphine waiver status of
practitioners who can prescribe medication (i.e., waivered
practitioners compared to non-waivered practitioners).

Practitioners
Of the 246 practitioners who responded to the contact survey and were invited to complete the
baseline needs assessment survey, 159 went on to complete the practitioner survey, and 152
responded to substantive survey questions (i.e., any questions other than role, work setting, and
work location). Our final cohort of practitioners includes these 152 respondents (response
rate=62%).

1

For the purposes of this report, partially rural counties (those with some rural census tracts and some non-rural
census tracts; see Section II of the document linked below) are considered non-rural.
https://data.hrsa.gov/Content/Documents/tools/rural-health/forhpeligibleareas.pdf
PAGE 5

UVMCORA.ORG

NEW HAMPSHIRE: PRACTITIONERS AND STAKEHOLDERS

Community Stakeholders
Of the 148 community stakeholders who responded to the contact survey and were invited to
complete the baseline needs assessment survey, 104 went on to complete the community
stakeholder survey, and 101 responded to substantive survey questions (i.e., any questions outside
of work setting and work location). Our final cohort of community stakeholders includes these 101
respondents (response rate=68%).

Rural County Location
Practitioners
Practitioner responses (n=152) included representation from all 10 New Hampshire counties (Table
1). Of these respondents, 81 (53%) reported working in at least one rural county, whereas 70 (46%)
reported working only in non-rural counties. One practitioner reported working in multiple New
Hampshire counties but did not provide sufficient information to determine whether they worked in
rural counties or not. The most-represented rural county was Grafton (20% of all responses),
whereas the most-represented non-rural county was Hillsborough (30% of all responses).
Table 1. Practitioner responses by New Hampshire county.
NH county in which
practitioner works

Total
Freq.

Percent

Rural Counties
Grafton
Multiple counties (rural)*
Carroll
Coos
Merrimack
Cheshire
Belknap
Sullivan

30
17
7
7
7
5
4
4

19.7
11.2
4.6
4.6
4.6
3.3
2.6
2.6

Non-Rural Counties
Hillsborough
Strafford
Rockingham
Multiple counties (non-rural)**

45
13
11
1

29.6
8.6
7.2
0.7

Multiple counties (unknown)***
Total

1
152

0.7
100

*Practitioners working in at least one rural New Hampshire county.
**Practitioners who reported only working in non-rural New Hampshire counties.
***One practitioner did not provide sufficient information to determine whether they worked in rural New Hampshire
counties or not, however they did respond that they worked in New Hampshire, in multiple counties.
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Community Stakeholders
Community stakeholder responses (n=101) also included representation from all 10 New Hampshire
counties (Table 2). Of these, 74 (73%) respondents reported working in rural counties, whereas 27
(27%) reported working only in non-rural counties. Respondents were well-distributed across all
counties. The most represented rural county was Grafton (13% of all responses), whereas the most
represented non-rural county was Hillsborough (13% of all responses).
Table 2. Community stakeholder responses by New Hampshire county.
NH county in which
community stakeholder works

Total
Freq.

Percent

Rural Counties
Grafton
Multiple counties (rural)*
Coos
Carroll
Cheshire
Merrimack
Sullivan
Belknap

13
12
11
10
9
8
7
4

12.9
11.9
10.9
9.9
8.9
7.9
6.9
4.0

13
10
4
101

12.9
9.9
4.0
100

Non-Rural Counties
Hillsborough
Strafford
Rockingham
Total
*Community stakeholders working in at least one rural New Hampshire county.
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Work Setting and Role
Practitioners
Table 3 shows the distribution of work settings among practitioner respondents (n=152) working in
rural (n=81) and non-rural (n=70) counties. Practitioners reported working in a wide variety of
settings including Federally Qualified Health Centers (FQHCs) or Rural Health Clinics (RHCs) (15%),
community hospitals (15%), and community mental health centers (13%). In addition, many
practitioner respondents reported working in SUD treatment settings, including addiction specialty
treatment providers (9%) and opioid treatment programs (7%).
Table 3. Rural and non-rural practitioner work settings.
Rural
Freq. Percent
Federally Qualified Health Center or Rural
Health Clinic
Community hospital
Community mental health center
Addiction specialty treatment provider
Hospital-owned practice
Private practice
Other
Academic medical center
Opioid treatment program
Corrections
Family Resource Center
Peer recovery
Hospital (non-academic, non-community)
Behavioral health clinic
Urgent care
Recovery Community Organization
Total

14
6
8
7
6
6
7
10
5
4
3
2
1
1
0
1
81

17.3
7.4
9.9
8.6
7.4
7.4
8.6
12.4
6.2
4.9
3.7
2.5
1.2
1.2
0
1.2
100

Non-rural
Freq. Percent

Total
Freq.
Percent

9
16
12
7
8
5
4
0
5
2
0
0
1
0
1
0
70

23
23
20
14
14
11
11
10
10
6
3
2
2
1
1
1
152

12.9
22.9
17.1
10.0
11.4
7.1
5.7
0
7.1
2.9
0
0
1.4
0
1.4
0
100

15.1
15.1
13.2
9.2
9.2
7.2
7.2
6.6
6.6
3.9
2.0
1.3
1.3
0.7
0.7
0.7
100
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Table 4 shows the professional roles of New Hampshire practitioner respondents (n=152) working in
rural (n=81), non-rural (n=70), and unknown (n=1) counties. Among practitioner respondents, there
were 71 counselors, case managers, psychologists, and recovery coaches (42 rural, 29 non-rural;
hereinafter referred to as “counselors”), and 81 clinicians and pharmacists (39 rural, 41 non-rural, 1
unknown; hereinafter referred to as “clinicians”). There were 55 clinicians (nurse practitioners,
primary care physicians, specialist physicians, advance practice nurses, and physician assistants) that
we grouped together for some analyses because they were able to prescribe medications (28 rural,
27 non-rural; hereinafter referred to as “prescribing clinicians”). The remaining 26 clinicians (11 rural,
14 non-rural, 1 unknown) were not able to prescribe medications (nurses, nursing or medical
assistants, and pharmacists).
Table 4. Rural and non-rural practitioner roles.
Rural
Freq. Percent

Non-rural
Freq. Percent

Total
Freq. Percent

Prescribing Clinicians
Nurse Practitioner
Primary Care Physician
Specialist Physician
Advanced Practice Nurse
Physician Assistant
Multiple

13
9
4
2
0
0

16.1
11.1
4.9
2.5
0
0

14
10
1
0
1
1

20.0
14.3
1.4
0
1.4
1.4

27
19
5
2
1
1

17.8
12.5
3.3
1.3
0.7
0.7

Non-Prescribing Clinicians
Nurse
Other
Nursing or Medical Assistant
Pharmacist

6
2
2
1

7.4
2.5
2.5
1.2

11
2
1
0

15.7
2.9
1.4
0

18
4
3
1

11.8
2.6
2.0
0.7

Counselors
Counselor
Alcohol and Drug Counselor
Recovery Coach
Case Manager
Other
Psychologist

11
10
10
8
2
1

13.6
12.4
12.4
9.9
2.5
1.2

14
9
3
2
1
0

20.0
12.9
4.3
2.9
1.4
0

25
19
13
10
3
1

16.6
12.6
8.6
6.6
2.0
0.7

Total

81

100

70

100

152*

100

*One practitioner did not provide sufficient information to determine whether they worked in rural New Hampshire
counties or not.

Among the prescribing clinicians that provided their specialty (n=47 of 55 total prescribing clinicians),
40% reported specializing in family medicine/general practice. Table 5 shows the distribution of
specialties among rural (n=24) and non-rural (n=23) prescribing clinicians.
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Table 5. Rural and non-rural practitioner specialties.
Rural
Freq.
Percent
Family medicine/general practice
Addiction medicine
Psychiatry
Multiple/other
Internal medicine
Pediatrics
Emergency/urgent care
Total

6
5
4
4
2
2
1
24

Non-rural
Freq.
Percent

25.0
20.8
17.4
16.7
8.3
8.3
4.2
100

13
2
2
0
2
1
1
23

56.5
8.7
8.3
0
8.7
4.4
4.3
100

Freq.

Total
Percent

19
7
6
4
4
3
2
47

40.4
14.9
12.8
8.5
8.5
6.4
4.3
100

Community Stakeholders
Table 6 shows the distribution of work settings among rural (n=74) and non-rural (n=27) community
stakeholders who responded to the question (total n=101). Community stakeholder work settings
included fire and/or emergency medical services (19%), child welfare (13%), health care/hospital
(13%) and community mental health (11%). In addition, there were several community stakeholder
respondents working in addiction specialty provider settings (7%), recovery community
organizations (RCOs) and recovery centers (6%), and family resource centers or family support
settings (4%).
Table 6. Community stakeholder work settings
Rural

Family Resource Center/family support
Public health
Recovery Community Organization/recovery center
Other
Health care/hospital
Library
Community mental health
Fire and/or emergency medical
Addiction specialty provider
Education & school health
Community coalition
Child welfare
Total

Freq.
18
10
8
7
7
4
5
3
5
2
3
2
74

Percent
24.3
13.5
10.8
9.5
9.5
5.4
6.8
4.1
6.8
2.7
4.1
2.7
100

Non-rural
Freq.
1
3
5
4
1
4
2
3
1
2
1
0
27

Percent
3.7
11.1
18.5
14.8
3.7
14.8
7.4
11.1
3.7
7.4
3.7
0
100

Total
Freq.
19
13
13
11
8
8
7
6
6
4
4
2
101
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Practitioner Waiver and Ability to Treat OUD
Among prescribing clinicians that reported their waiver status (n=47 of 55 total prescribing
clinicians), 60% reported having a waiver to prescribe buprenorphine2 at the time of the survey
(Table 7).
Table 7. Buprenorphine waiver status of rural and non-rural prescribing clinicians (i.e., MD, DO, NP, PA).
Rural
Non-rural
Total
Freq.
Percent
Freq.
Percent
Freq.
Percent
Waivered
Not waivered
Total

15
9
24

62.5
37.5
100

13
10
23

56.5
43.5
100

28
19
47

59.6
40.4
100

Among prescribing clinicians who responded to the question (n=45), 23 reported currently treating
patients with OUD using U.S. Food and Drug Administration-approved MOUD (e.g., methadone,
buprenorphine, naltrexone) (Table 8). Of these 23 practitioners, 22 (94%) were waivered to prescribe
buprenorphine, and 91% reported primarily prescribing buprenorphine (Table 9).
Table 8. Rural and non-rural practitioners currently treating patients with opioid use disorder (OUD) using
U.S. Food & Drug Administration-approved medications for OUD (MOUD).
Rural
Non-rural
Total
Freq.
Percent
Freq.
Percent
Freq.
Percent
Treating OUD with medications
13
56.5
10
45.5
23
51.1
Not treating OUD with medications
10
43.5
12
54.6
22
48.9
Total
23
100
22
100
45
100

Table 9. Primary medication prescribed by practitioners currently treating patients with opioid use disorder
(OUD) using U.S. Food & Drug Administration-approved medications for OUD (MOUD).
Rural
Non-rural
Total
Freq.
Percent
Freq.
Percent Freq.
Percent
Buprenorphine
11
84.6
10
100
21
91.3
Methadone
1
7.7
0
0
1
4.4
Naltrexone
1
7.7
0
0
1
4.4
Total

13

100

10

100

23

100

2

The 2021 change to federal practice guidelines allowing practitioners to obtain a waiver to treat up to 30 patients with
buprenorphine without a training requirement was not in effect at the time of the survey.
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Practitioner Difficulty Retaining Patients

Difficulty Retaining Patients (Scale 0-10)

Practitioners currently treating patients with OUD using MOUD who responded to the question
(n=22) reported a moderate level of difficulty (scale 0–10; mean score=5.1) retaining patients on
their recommended MOUD treatment regimen, with one-third (32%) reporting a difficulty level of 7
or higher (Figure 2).

Figure 2. Distribution of reported difficulty retaining patients in their medication for opioid use disorder
(MOUD) treatment regimens among practitioners currently treating patients using MOUD (n=22).

Figure 3 shows box and whisker plots3 of the distribution of difficulty levels reported by rural (n=12)
and non-rural (n=10) prescribing clinicians currently treating patients with MOUD regarding retaining
patients in their MOUD treatment regimens. Using an independent samples t-test, there was no
significant difference using a cutoff of p<0.05 between the mean difficulty level reported by rural
and non-rural practitioners. Most prescribing clinicians (82%) reported that their patients stay in
treatment for six months or longer. Using a chi-square test of independence, there was no significant
difference between the proportion of rural and non-rural practitioners that reported that their
patients stay in treatment for six months or longer (data not shown).

3

For further description of data distribution in boxplots, please consult:
https://www.open.edu/openlearn/ocw/mod/oucontent/view.php?printable=1&id=4089
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Figure 3. Box and whisker plot showing quartiles of the distribution of difficulty levels in retaining patients
on MOUD treatment regimens, as reported by rural (n=12) and non-rural (n=10) practitioners currently
treating patients using MOUD. Middle lines of the colored boxes represent median values and left and right
lines represent 25th and 75th percentile values, respectively. The leftmost and rightmost lines represent the
lower and upper adjacent values of the distribution. In this figure, the 25th percentile value (3) among nonrural practitioners is the same as the minimum value. Similarly, the median value (5) is the same as the 75 th
percentile value. There are no outlier values.

Practitioner Concern about Treatment Adherence

Level of Concern (Scale 0-10)

Figure 4 shows the distribution of practitioners’ levels of concern regarding patient non-adherence
to the recommended MOUD treatment regimen, among practitioners currently treating patients
using MOUD (n=23). The average level of concern was moderate (mean score=4.5), with fewer than
one-third (30%) reporting a level of concern of 7 or higher.

Figure 4. Distribution of concern regarding patient non-adherence to the recommended medication for
opioid use disorder (MOUD) treatment regimen, among practitioners currently treating patients with MOUD
(n=23).
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Figure 5 shows box and whisker plots of the distribution of concern that rural (n=13) and non-rural
(n=10) prescribing clinicians currently treating patients with MOUD reported regarding patient nonadherence to the recommended MOUD treatment regimen. Using an independent samples t-test,
there was no significant difference between the mean concern level of rural (mean score=4.8) and
non-rural (mean score=4.2) practitioners regarding patient non-adherence to the recommended
MOUD treatment regimen.

Figure 5. Box and whisker plot showing quartiles of the distribution of concern regarding patient nonadherence to the recommended medication for opioid use disorder (MOUD) treatment regimen, among
rural (n=13) and non-rural (n=10) practitioners currently treating patients with MOUD. Middle lines of the
colored boxes represent median values and left and right lines represent 25th and 75th percentile values,
respectively. The leftmost and rightmost lines represent the lower and upper adjacent values of the
distribution. In this figure, among non-rural practitioners the 75th percentile value (7) is the same as the
maximum value. There are no outlier values.

Number of Patients: Total and OUD Treatment
Table 10 shows the number of patients cared for each week by practitioners for all reasons. Among
practitioners who responded to the question (n=151), five practitioners reported seeing zero
patients per week; these individuals reported working in nursing, case management, and other roles,
with four reporting working in management positions. Additionally, seven practitioners reported
seeing 100 or more patients per week, two of whom reported seeing over 400. Among these seven
were two nurses, two nurse practitioners, a case manager, a primary care physician, and a
psychologist.

PAGE 14

UVMCORA.ORG

NEW HAMPSHIRE: PRACTITIONERS AND STAKEHOLDERS

Table 10. Number of unique patients cared for each week by practitioners (for all reasons), grouped by rural
location, buprenorphine waiver status, and role group.
N

Mean

Median

Min

Max

151
80
70

35.3
31.3
40.0

25
20
25

0
0
0

460
100
460

Waivered prescribing clinicians
Non-waivered prescribing clinicians

23
22

40.4
45.5

40
45

10
1

100
200

Clinicians
Counselors

81
70

44.5
24.6

35
20

0
0

460
100

All practitioners
Rural practitioners*
Non-rural practitioners*

*One practitioner did not provide sufficient information to determine whether they worked in rural New Hampshire
counties or not.

Table 11 shows the number of patients that practitioners with buprenorphine waivers who
responded to the question (n=22) reported treating with MOUD at any one time. Seven (36%)
respondents reported treating five or fewer patients, while six (23%) reported treating 50 or more
patients, including two who reported treating 100 or more patients.
Table 11. Number of patients treated by practitioners (n=22) using medications for opioid use disorder
(MOUD) at any one time, by work location.

All practitioners currently treating patients with MOUD
Rural
Non-rural

N

Mean

Median

Min

Max

22
12
10

54.0
65.7
40.1

22
10
32

0
0
3

600
600
100

Concern about Substances
Practitioners
Practitioners were asked to report their level of concern (scale 0–10) regarding the use of different
substances and substance combinations (Table 12). Throughout this section, we use independent
samples t-tests with a conservative cutoff of p<0.01 to account for multiple comparisons to
determine statistical significance.
Practitioners were most concerned about fentanyl (mean score=7.9), methamphetamine (mean
score=7.5) and the combinations of opioids with stimulants (mean score=7.7), alcohol (mean
score=7.5) and sedatives (e.g., benzodiazepines; mean score=7.4).
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Table 12. Practitioners’ mean level of concern (scale 0–10) regarding use of various substances among their
patients.
N
N*
Mean
Mean
Fentanyl
149
7.9
Tobacco
146
6.3
Opioids + stimulants
146
7.7
Cocaine
149
6.2
Opioids + alcohol
149
7.5
Benzodiazepines
149
6.2
Methamphetamine
147
7.5
Rx stimulants
150
5.5
Heroin
150
7.4
Marijuana
146
5.4
Opioids + sedatives
148
7.4
Other street drugs
146
4.8
Alcohol
151
7.3
Over-the-counter or
142
4.8
prescription drug misuse
Rx opioids
150
6.4
*Sample sizes differ between substances because not all practitioners provided a level of concern for every substance.

Figure 6 shows the mean level of concern regarding the use of different substances among waivered
and non-waivered practitioners. There were no significant differences in mean concern levels
reported by waivered and non-waivered practitioners regarding their patients’ use of these
substances, among all practitioners (Figure 6) and rural practitioners only (data not shown).

Figure 6. Mean level of concern among waivered (sample size range: n=27–28) and non-waivered (sample
size range: n=17–19) practitioners regarding their patients’ use of substances, ordered by waivered
practitioner concern. OTC: over-the-counter; Rx: prescription.
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Figure 7 shows the mean level of concern regarding the use of different substances among rural
(sample size range: n=77–80) and non-rural (sample size range: n=64–70) practitioners. There were
no significant differences between rural and non-rural practitioners’ mean concern levels regarding
their patients’ use of these substances.

Figure 7. Mean level of concern among rural (sample size range n=77–80) and non-rural (sample size range
n=64–70) practitioners regarding their patients’ use of substances, ordered by rural practitioner concern.

Figure 8 shows the mean level of concern regarding the use of different substances among clinicians
(sample size range: n=76–80) and counselors (sample size range: n=66–71). Clinicians reported
significantly greater concern about their patients’ tobacco use (mean score=7.1) compared to
counselors (mean score=5.4; p=0.001). There were no significant differences between these groups
for other substances. When limiting the analysis to rural practitioners only, there were no significant
differences between clinicians’ and counselors’ mean levels of concern regarding their patients’ use
of these substances (data not shown).
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Figure 8. Mean level of concern among clinicians (sample size range: n=76–80) and counselors (sample size
range n=66–71); see Table 4 for more information on these role groups) regarding their patients’ use of
substances, ordered by level of concern among clinicians. OTC: over-the-counter; Rx: prescription.

Community Stakeholders
Table 13 shows community stakeholders’ reported levels of concern (scale 0–10) regarding the use
of substances and substance combinations in the communities in which they work. Community
stakeholders were most concerned about fentanyl (mean score=8.3), methamphetamine (mean
score=8.0), heroin (mean score=7.9), and the combinations of opioids with alcohol (mean score=7.9)
and stimulants (mean score=7.9).

Table 13. Community stakeholders’ mean level of concern (scale 0–10) about use of substances in the
communities in which they work.

Fentanyl
Methamphetamine
Opioids + stimulants
Heroin
Opioids + alcohol
Alcohol
Rx opioids
Opioids + sedatives

N* Mean
100
8.3
Rx stimulants
100
8
Cocaine
100
7.9
Tobacco
100
7.9
Benzodiazepines
99
7.9
Other street drugs
101
7.8
Over-the-counter or prescription drug misuse
100
7.8
Marijuana
99
7.4

N*
100
99
100
100
101
99
98

Mean
6.8
6.6
6.5
6.2
5.8
5.6
5.5

*Sample sizes differ because not all stakeholders provided a level of concern for every substance.

PAGE 18

UVMCORA.ORG

NEW HAMPSHIRE: PRACTITIONERS AND STAKEHOLDERS

Figure 9 shows the mean level of concern among practitioners (sample size range: n=142–151) and
community stakeholders (sample size range: n=98–101) regarding substance use among the patients
and communities with whom they work. Using independent samples t-tests with a conservative
cutoff of p<0.01 (to account for multiple comparisons), community stakeholders (mean score=6.8)
had a 1.3-point greater average concern level regarding the use of prescription stimulants than
practitioners (mean score 5.5; p<0.0005). Community stakeholders (mean score=7.8) had a 1.4-point
greater concern level about the use of prescription opioids than practitioners (mean score=6.4;
p<0.0005).

Figure 9. Mean level of concern among practitioners (sample size range: n=142–151) and community
stakeholders (sample size range: n=98–101) regarding substance use among the patients and communities
with whom they work. OTC: over-the-counter; Rx: prescription.
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Figure 10 shows the mean level of concern among rural (sample size range: n=72–74) and non-rural
(sample size range: n=26–27) community stakeholders regarding substance use in the communities
in which they work. Using independent samples t-tests with a conservative cutoff of p<0.01 (to
account for multiple comparisons), there were no significant differences in concern levels between
rural and non-rural community stakeholders (p-values>0.05).

Figure 10. Mean level of concern among rural (sample size range n=72–74) and non-rural (sample size range
n=26–27) community stakeholders regarding substance use in the communities in which they work. OTC:
over-the counter; Rx: prescription.
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Practitioner Comfort Treating SUD

Comfort Level (Scale 0–10)

Practitioners were asked to report their level of comfort in treating patients with OUD and in treating
SUD in special populations. Throughout this section we use independent samples t-tests with a cutoff
of p<0.05 to determine statistical significance. Figure 11 shows the distribution of practitioners’ level
of comfort in treating patients with OUD (scale 0–10). Practitioner respondents reported an average
comfort level of 7.6, with 31% rating their comfort level as 10 out of 10 and 70% reporting their
comfort level as 7 or higher.

Figure 11. Distribution of practitioner responses to the question, “How comfortable are you
addressing/treating opioid use disorder in your patients?” (Scale 0-10).

The following three boxplots present the distribution of practitioner comfort in treating OUD,
stratified by practitioner waiver status (Figure 12), rurality (Figure 13), and role type (Figure 14).
Waivered practitioners (n=28) reported significantly greater comfort in treating patients with OUD
(mean score=8.2) compared to non-waivered practitioners (n=19; mean score=5.5; p<0.0005) (Figure
12). This difference persisted when limiting the analysis to rural waivered (n=15; mean score=8.3)
and rural non-waivered (n=9; mean score=6.0; p=0.016) practitioners.

PAGE 21

UVMCORA.ORG

NEW HAMPSHIRE: PRACTITIONERS AND STAKEHOLDERS

Figure 12. Box and whisker plot showing comfort treating opioid use disorder (OUD) among waivered (n=28)
and non-waivered (n=19) practitioners. Middle lines of the colored boxes represent median values and left
and right lines represent 25th and 75th percentile values, respectively. The leftmost and rightmost lines
represent the lower and upper adjacent values of the distribution, and dots outside the lines represent
outlier values. In this figure, the maximum value among waivered practitioners (10) is the same as the 75th
percentile value.

There was no significant difference in the mean comfort level of rural (n=79; mean score=7.6) and
non-rural (n=69; mean score=7.7) practitioners in treating patients with OUD (Figure 13).

Figure 13. Box and whisker plot showing comfort treating opioid use disorder (OUD) among rural (n=79) and
non-rural (n=69) practitioners. Middle lines of the colored boxes represent median values and left and right
lines represent 25th and 75th percentile values, respectively. The leftmost and rightmost lines represent the
lower and upper adjacent values of the distribution. In this figure, the maximum value among rural and nonrural practitioners (10) is the same as the 75th percentile values. There are no outliers.

Counselors (mean score=8.3) reported significantly greater comfort treating OUD than clinicians
(mean score 7.0; p=0.001) (Figure 14). This difference persisted, but was not significant, when
limiting the sample to rural counselors (n=41; mean score=8.1) and clinicians (n=38; mean
score=7.1).
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Figure 14. Box and whisker plot showing comfort level in treating opioid use disorder (OUD) among
clinicians (n=79) and counselors (n=70). Middle lines of the colored boxes represent median values and left
and right lines represent 25th and 75th percentile values, respectively. The leftmost and rightmost lines
represent the lower and upper adjacent values of the distribution, and dots outside the lines represent
outlier values. In this figure, the maximum value among counselors (10) is the same as the 75th percentile.

Figure 15 shows practitioner respondents’ mean comfort levels in treating SUD among special
populations. Practitioners reported the most comfort in treating older adults (mean score=6.4), and
the least comfort in treating adolescents (mean score=3.9).

Figure 15. Mean comfort level in providing substance use disorder (SUD) services to special populations
among all practitioner respondents (sample size range: n=144–147).
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Figure 16 shows mean practitioner comfort level in providing SUD services to special populations
among prescribing clinicians with buprenorphine waivers (sample size range n=26–28) and without
buprenorphine waivers (sample size range n=18–19).
In treating older adults, waivered practitioners had over a three-point greater mean comfort level
than non-waivered practitioners (p<0.0005). This difference persisted when limiting the analysis to
rural practitioners only (waivered n=15, non-waivered n=9; p=0.005) (Figure 16).
In providing SUD care to pregnant patients, buprenorphine-waivered practitioners reported a twopoint greater mean comfort level than non-waivered practitioners (Figure 16; p=0.031). This
difference was not significant when limiting the analysis to rural practitioners only (waivered n=14,
non-waivered n=9; data not shown)
There were no significant differences in mean comfort level between waivered and non-waivered
practitioners in providing family-based SUD interventions and support for families of individuals with
SUDs or in providing SUD care or counseling for adolescents or minors (Figure 16). When limiting the
sample to rural practitioners only, there were also no significant differences in mean comfort levels
for these two special populations based on practitioner waiver status (data not shown).

Figure 16. Mean comfort level in providing substance use disorder (SUD) services to special populations
among waivered (sample size range n=26–28) and non-waivered (sample size range n=18–19) practitioners.
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Figure 17 shows mean comfort level in providing SUD services to special populations among rural
(sample size range n=78–80) and non-rural (sample size range n=64–69) practitioners. There were
no significant differences between rural and non-rural practitioners’ comfort in treating any of these
special populations.

Figure 17. Mean comfort level in providing substance use disorder services to special populations among
rural (sample size range n=78–80) and non-rural (sample size range n=64–69) practitioners.
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Figure 18 shows mean comfort level in providing SUD services to special populations among clinicians
(sample size range n=75–79) and counselors (sample size range n=67–69). In treating older adults,
counselors had a one-point higher mean comfort level than clinicians (p=0.03). Among rural
practitioners only, there was no significant difference. There were no significant differences in mean
comfort level between counselors and clinicians in providing SUD care to pregnant patients,
providing family-based SUD interventions and support for families of individuals with SUDs, or
providing SUD care or counseling for adolescents or minors (Figure 18). When limiting the sample to
rural practitioners only, there were also no significant differences in mean comfort level in providing
substance use disorder services to these special populations based on practitioner role group (data
not shown).

Figure 18. Mean comfort level in providing substance use disorder services to special populations among
clinicians (sample size range n=75–79) and counselors (sample size range n=67–69). (See Table 4 for more
information on these role groups).
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Training and Supports
Prescribing clinicians were asked, “To what degree do you feel you have the training, experience,
and supports you need to induct patients on opioid treatment medication? (Scale 0–10)” The
average self-rated training, experience, and support level was 6.2; 55% of respondents reported
scores of 7 or higher. Table 14 shows practitioner training, experience, and support to induct patients
on MOUD by rurality and buprenorphine waiver status. Figure 19 shows the distribution of training,
experience, and support levels among all respondents. Throughout this section we use independent
samples t-tests with a cutoff of p<0.05 to determine statistical significance.
Table 14. Practitioner perception of having adequate training, experience, and support to induct patients on
medications for opioid use disorder by rural location and buprenorphine waiver status (scale 0–10).
Mean

All Practitioners

38

6.2

Rural
Non-rural

20
18

6.2
6.3

Waivered
Not waivered

28
10

7.3
3.3

Self-Rated Training, Experience, and Support
Level (Scale 0-10)

N

Figure 19. Prescribing clinicians’ (n=38) perceptions of having adequate training, experience, and supports
to induct patients on medications for opioid use disorder (MOUD).
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Figure 20 shows the distribution of self-rated training, experience, and support level among rural
(n=20) and non-rural (n=18) prescribing clinicians. There was no significant difference in mean selfrated training, experience, and support level between rural (mean score=6.2) and non-rural (mean
score=6.3) practitioners.

Figure 20. Box and whisker plot showing the distribution of self-rated training, experience, and support to
induct patients on medications for opioid use disorder (MOUD), among rural (n=20) and non-rural (n=18)
practitioners. Middle lines of the colored boxes represent median values, left and right lines represent 25th
and 75th percentile values respectively. The leftmost and rightmost lines represent the lower and upper
adjacent values of the distribution, and dots outside the lines represent outlier values.
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Figure 21 shows the distribution of self-rated training, experience, and support levels among
waivered (n=28) and non-waivered (n=10) prescribing clinicians. Waivered practitioners reported a
four-point higher training, experience, and support level (mean=7.3) than non-waivered
practitioners (mean=3.3; p<0.0005).4 This difference persisted among rural practitioners only,
although the magnitude of the difference was smaller (waivered n=15, mean=6.8; non-waivered n=5,
mean=4.4; p=0.047).

Figure 21. Box and whisker plot showing the distribution of self-rated training, experience, and support to
induct patients on medications for opioid use disorder (MOUD), among waivered (n=28) and non-waivered
(n=10) practitioners. Middle lines of the colored boxes represent median values, left and right lines
represent 25th and 75th percentile values respectively. The leftmost and rightmost lines represent the
lower and upper adjacent values of the distribution. There are no outlier values.

Treatment Barriers
Practitioners
Practitioners were asked about barriers to treating and retaining patients with OUD, as well as
patient-related barriers to OUD treatment. Throughout this section, we use chi-square tests of
independence to examine the relationship between practitioner characteristics and reported
barriers to treating patients with OUD. For all statistical tests in this section, we use a conservative
cutoff of p<0.01 to account for multiple comparisons.

4

This difference is notable given the 2021 change to federal practice guidelines, which allows practitioners to obtain a
waiver to prescribe buprenorphine without completing training. Although removing the training requirement
eliminates a barrier, many non-waivered practitioners report that they do not have the training, experience, and
support needed to induct patients onto medication for OUD.
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Figure 22 shows practitioner-identified top barriers to their practices treating patients with OUD and
retaining patients in OUD treatment.

Figure 22. Practitioner-identified top barriers to their practices treating patients with opioid use disorder
(OUD) (n=149) and retaining patients in OUD treatment (n=22; only practitioners that reported currently
treating patients using FDA-approved medications for OUD were asked about barriers to retaining patients).
Note: “MOUD effectiveness concerns” was asked as a barrier to treating patients, “Inflexible treatment
protocols” was asked as a barrier to retaining patients.

Over half of New Hampshire practitioners who responded to the question (n=149) identified
constraints on time or staffing as a top barrier to treating patients. Among practitioners currently
treating patients with MOUD (n=22), 68% identified constraints on time or staffing as a top barrier
to retaining patients. Around half of practitioners identified organizational and clinical barriers as
top barriers to treating patients with OUD and retaining them in treatment.
Notably, approximately one in five practitioners identified “other” top barriers to treating (19%) and
retaining patients (18%) in treatment for OUD. These other barriers included lack of available
housing, lack of available counseling or social work support for patients (especially un- and underinsured patients), and lack of affordable treatment options.
Figure 23 shows the top barriers to treating patients with OUD identified by waivered (n=28) and
non-waivered (n=19) prescribing practitioners. A significantly higher proportion of non-waivered
practitioners (74%) identified training as a top barrier compared to waivered practitioners (29%;
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p=0.002). Additionally, a significantly higher proportion of waivered practitioners (36%) indicated
insurance or reimbursement issues as a top barrier to treating patients, compared to none (0%) of
the non-waivered practitioners (p=0.003). Among rural practitioners only (waivered n=15, nonwaivered n=9), this association persisted, but was not statistically significant (data not shown;
p=0.015). There were no significant associations between practitioner waiver status and any other
reported barriers among all practitioners.

Figure 23. Waivered (n=28) and non-waivered (n=19) practitioner-identified top barriers to their practices
treating patients with opioid use disorder (OUD).

Among rural practitioners only (waivered n=15, non-waivered n=9), a significantly higher proportion
of rural buprenorphine-waivered practitioners (93%) identified time and staffing constraints as a
barrier compared to non-waivered practitioners (44%, p=0.007). A significantly smaller proportion
of rural waivered practitioners (7%) identified concerns about managing OUD patients as a barrier
than that of rural non-waivered practitioners (56%, p=0.007). Other than the association regarding
insurance and reimbursement referenced in the paragraph above, there were no significant
associations between practitioner waiver status and reported barriers among rural practitioners.
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Figure 24 shows the top barriers to treating patients with OUD identified by rural (n=79) and nonrural (n=69) practitioners. There were no significant associations between practitioner rurality and
reported barriers.

Figure 24. Rural (n=79) and non-rural (n=69) practitioner-identified top barriers to their practices treating
OUD among their patients.
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Figure 25 shows the top barriers to treating patients with OUD identified by clinicians (n=79) and
counselors (n=70). A greater proportion of counselors (49%) identified stigma of OUD as a top barrier
compared to clinicians (24%; p=0.002). There were no other significant associations between
practitioner role group and reported barriers to treating patients with OUD.

Figure 25. Clinician- (n=79) and counselor- (n=70) identified top barriers to their practices treating OUD
among their patients.

Among rural practitioners only (counselors n=41, clinicians n=38), the association between
practitioner role group and identification of stigma as a top barrier to OUD treatment remained: a
greater proportion of rural counselors (51%) identified stigma of OUD as a top barrier compared to
rural clinicians (21%, p=0.005). There were no other significant associations between practitioner
role group and reported barriers to treating patients with OUD among rural practitioners.
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Figure 26 shows the proportion of practitioners that identified various top barriers to patients
receiving (n=150) and remaining in (n=147) OUD treatment. Lack of time, transportation, and other
supports was identified by most practitioners as a top barrier to patients receiving (79%) and
remaining in (84%) OUD treatment. Among those identifying a lack of time, transportation, and other
supports as their primary concern for patients receiving treatment (n=45), 40 (89%) noted
transportation or other access issues, 34 (76%) identified lack of social support, 20 (44%) noted lack
of time due to childcare, and 4 (9%) noted a lack of language support or interpretive services. Other
frequently endorsed top barriers included stigma of OUD (receiving treatment: 59%, remaining in
treatment: 46%), insurance or reimbursement issues (receiving treatment: 39%, remaining in
treatment: 42%), concerns about treatment and co-occurring health issues (receiving treatment:
40%, remaining in treatment: 38%), and family or parenting demands (receiving treatment: 33%,
remaining in treatment: 41%).

Figure 26. Practitioner-identified top barriers to patients receiving (n=150) and remaining in (n=147) opioid
use disorder (OUD) treatment.
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Figure 27 shows patient-related barriers to OUD treatment as identified by waivered (n=28) and nonwaivered (n=19) prescribing clinicians. There were no significant associations between practitioner
waiver status and reported patient-related barriers to OUD treatment. Similarly, among rural
practitioners only (waivered n=15, non-waivered n=9), there were no significant associations
between practitioner waiver status and reported patient-related barriers to OUD treatment.

Figure 27. Patient-related barriers to receiving opioid use disorder (OUD) treatment identified by waivered
(n=28) and non-waivered (n=19) practitioners.
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Figure 28 shows the proportion of rural (n=80) and non-rural (n=69) practitioners that identified
various barriers among their top barriers to patients to receiving OUD treatment. A greater
proportion (43%) of rural practitioners identified parenting and family concerns as a top barrier to
patients receiving OUD treatment compared to non-rural practitioners (22%; p=0.007). There were
no other significant associations between the rurality of practitioner rurality and reported patientrelated barriers to treatment.

Figure 28. Patient-related barriers to receiving opioid use disorder (OUD) treatment identified by rural
(n=80) and non-rural (n=69) practitioners.

Figure 29 shows the proportion of clinicians (n=79) and counselors (n=71) that identified barriers as
among their top-three barriers to patients to receiving OUD treatment. There were no significant
associations between the role type of practitioners and patient-related barriers to treatment that
they reported. Similarly, among rural practitioners only (clinicians n=38; counselors n=42), there
were no significant associations between the role type of practitioners and patient-related barriers
to treatment that they reported.
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Figure 29. Patient-related barriers to receiving opioid use disorder (OUD) treatment identified by
practitioners in clinician & pharmacist (n=79) and counseling, case manager, and recovery coach (n=70)
roles.

Community Stakeholders
Community stakeholders were asked to identify the greatest challenges to treating OUD in the
communities in which they work. Throughout this section, we use chi-square tests of independence
to examine the relationship between stakeholder characteristics and reported challenges to treating
OUD. For all statistical tests in this section, we use a conservative cutoff of p<0.01 to account for
multiple comparisons.
Table 15 shows the proportion of community stakeholders who responded to the question (n=99)
that identified various challenges among the top three challenges to treating OUD in their
communities. Over half (56%) of community stakeholders identified patient access barriers (e.g.,
transportation, time, and childcare) as a top challenge. This is consistent with practitioner
respondents who similarly were most likely to identify time, transport, and other supports, as a top
barrier to patients receiving treatment. Other key challenges reported by community stakeholders
included lack of capacity to treat patients in their communities (42%), and stigma of OUD (40%)
(Table 15).
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A greater proportion of non-rural community stakeholders (11%) identified medication diversion
concerns as a challenge compared to rural community stakeholders (0%; p=0.004); however, it is
important to note the small overall number of community stakeholders that identified this concern
(n=3, 3%). There were no other significant differences in challenges identified by rural (n=72) and
non-rural (n=27) community stakeholders.
Table 15. Community stakeholder- (n=99) identified challenges to treating patients with opioid use disorder
(OUD) in their communities.

Challenge to treating OUD
Barriers to accessing treatment for patients
(e.g., transportation, time, childcare)
Not enough capacity to treat patients
Stigma of opioid use disorder
Not enough care coordination for individuals
with complex needs (linkages to social supports
/ community resources)
Insurance barriers (e.g., lack of coverage, prior
authorization requirements, fail first
requirements)
Difficulty getting individuals to adhere to the
requirements of their treatment
Providers need more supports for treating OUD
(training, resources, assistance with waiver
process)
Misconceptions of medications used to treat
OUD (e.g., buprenorphine, methadone)
Difficulty retaining individuals in treatment
once they are enrolled (low retention)
Lack of adequate language support or
interpretive services
Concerns about diversion of treatment
medications (methadone, buprenorphine)
Other challenges
Pharmacy restrictions
Not enough administrative support for
providers (billing, reimbursement, scheduling)
Administrative/organizational buy-in or support

Rural
(n=72)
Freq. Percent

Non-Rural
(n=27)
Freq.
Percent

Total
(n=99)
Freq. Percent

42

58.3

13

48.2

55

55.6

29
31

40.3
43.1

13
9

48.2
33.3

42
40

42.4
40.4

27

37.5

11

40.7

38

38.4

27

37.5

8

29.6

35

35.4

19

26.4

8

29.6

27

27.3

10

13.9

7

25.9

17

17.2

12

16.7

3

11.1

15

15.2

7

9.7

4

14.8

11

11.1

7

9.5

0

0

7

6.9

0

0

3

11.1

3

3.0

1
1

1.4
1.4

1
1

3.7
3.7

2
2

2.0
2.0

1

1.4

0

0

1

1.0

0

0

0

0

0

0
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Beliefs
Practitioner (sample size range n=124–146) and community stakeholder (sample size range n=94–
96) respondents reported the degree to which they agreed with statements about SUD and SUD
treatment. Samples sizes vary because not all respondents answered each question. For all results
presented in this section, we combined responses of “somewhat agree” and “strongly agree” (also
referred to as “agree/strongly agree” in the text and figure legends below) and “somewhat disagree”
and “strongly disagree” (also referred to as “disagree/strongly disagree” in the text and figure
legends below). Throughout this section we use chi-square tests of independence with a statistical
significance threshold of p<0.05 to compare the proportion of respondents indicating that they
agree/strongly agree, versus those who responded that they disagree/strongly disagree combined
with those who selected “neither agree nor disagree.”
There was no significant difference between the proportion of practitioners (45%) and community
stakeholders (35%) that agreed or strongly agreed with the statement, “People in the community
where I work have adequate access to an effective form of substance use treatment when they
need it” (Figure 30).

Figure 30. Distribution of agreement among practitioners (n=143) and community stakeholders (n=96) with
the statement, “People in the community where I work have adequate access to an effective form of
substance use treatment when they need it.”

There were no significant differences in the proportion of practitioners that agreed or strongly
agreed with the statement, “People in the community where I work have adequate access to an
effective form of substance use treatment when they need it,” based on practitioner waiver status,
rurality or role type (Figure 31). Among rural practitioners only, there were also no significant
differences in the proportion of practitioners that agreed or strongly agreed with the statement
based on waiver status or role type (data not shown). There was also no significant difference in the
proportion of rural (36%) and non-rural (35%) community stakeholders that agreed or strongly
agreed that people in the community where they work have adequate access to an effective form of
substance use treatment when they need it (Figure 32).
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Figure 31. Distribution of agreement among practitioners by clinicians (n=76) vs. counselors (n=68);
waivered (n=27) vs. non-waivered (n=18) prescribing clinicians; and rural (n=78) vs. non-rural (n=64)
practitioners with the statement, “People in the community where I work have adequate access to an
effective form of substance use treatment when they need it.”

Figure 32. Distribution of agreement among rural (n=70) and non-rural community stakeholders (n=26) with
the statement, “People in the community where I work have adequate access to an effective form of
substance use treatment when they need it.”
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Figure 33, Figure 34, and Figure 35 show the distribution of agreement among practitioners and
community stakeholders with the statement, “If a person came to me and confided that they were
suffering from opioid addiction, I feel confident that I would know where to refer them for
treatment.”
There was no significant difference between the proportion of practitioners (83%) and community
stakeholders (75%) that agreed or strongly agreed with the statement, “If a person came to me and
confided that they were suffering from opioid addiction, I feel confident that I would know where
to refer them for treatment” (Figure 33).

Figure 33. Distribution of agreement among practitioners (n=144) and community stakeholders (n=97) with
the statement, “If a person came to me and confided that they were suffering from opioid addiction, I feel
confident that I would know where to refer them for treatment.”
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The proportion of counselors (91%) that agreed or strongly agreed with the statement, “If a person
came to me and confided that they were suffering from opioid addiction, I feel confident that I
would know where to refer them for treatment,” was significantly higher than that of clinicians
(76%; p=0.017) (Figure 34). There were no significant differences in practitioner agreement by waiver
status or rurality (Figure 34). Among rural practitioners only, there were no significant differences in
agreement with the statement by waiver status or role type (data not shown).

Figure 34. Distribution of practitioner agreement with the statement, “If a person came to me and confided
that they were suffering from opioid addiction, I feel confident that I would know where to refer them for
treatment,” stratified by role type (clinicians n=76 vs. counselors n=68); waiver status (waivered n=28 vs.
non-waivered n=18); and rurality (rural n=77 vs. non-rural n=66)
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There was no significant difference in the proportion of rural and non-rural community stakeholders
that agreed or strongly agreed with the statement, “If a person came to me and confided that they
were suffering from opioid addiction, I feel confident that I would know where to refer them for
treatment,” (Figure 35).

Figure 35. Distribution of agreement among rural and non-rural community stakeholders (n=96) with the
statement, “If a person came to me and confided that they were suffering from opioid addiction, I feel
confident that I would know where to refer them for treatment.”

Figure 36, Figure 37, and Figure 38 show the distribution of responses among practitioners (n=144)
and community stakeholders (n=97) with the statement, “If a person came to me and confided that
they were suffering from opioid use disorder, I feel confident that they would have access to
services from the place where I referred them for treatment.” There was no significant difference
between the proportion of practitioners (58%) and community stakeholders (49%) that agreed or
strongly agreed with the statement (Figure 36).

Figure 36. Distribution of agreement among practitioners (n=144) and community stakeholders (n=97) with
the statement, “If a person came to me and confided that they were suffering from opioid use disorder, I
feel confident that they would have access to services from the place where I referred them for
treatment.”
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The proportion of waivered practitioners (75%) that agreed or strongly agreed with the statement,
“If a person came to me and confided that they were suffering from opioid use disorder, I feel
confident that they would have access to services from the place where I referred them for
treatment,” was significantly higher than the proportion of non-waivered practitioners (44%;
p=0.036) (Figure 37). There were no significant differences in the proportion of practitioners that
agreed or strongly agreed with the statement based on practitioner role type and rurality. Among
rural practitioners only, there were no statistically significant differences between practitioner
agreement by waiver status or role type (data not shown).

Figure 37. Distribution of agreement among practitioners with the statement, “If a person came to me and
confided that they were suffering from opioid use disorder, I feel confident that they would have access
to services from the place where I referred them for treatment,” stratified by role type (clinicians n=76 vs.
counselors n=68); waiver status (waivered n=27 vs. non-waivered n=18); and rurality (rural n=78 vs. nonrural n=64)
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There was no significant difference in the proportion of rural and non-rural community stakeholders
that agreed or strongly agreed with the statement, “If a person came to me and confided that they
were suffering from opioid use disorder, I feel confident that they would have access to services
from the place where I referred them for treatment.” (Figure 38).

Figure 38. Distribution of agreement among rural (n=70) and non-rural (n=26) community stakeholders with
the statement, “If a person came to me and confided that they were suffering from opioid use disorder, I
feel confident that they would have access to services from the place where I referred them for
treatment.”

Figure 39, Figure 40, and Figure 41 show the distribution of responses among practitioners (n=145)
and community stakeholders (n=98) with the statement, “If a person came to me and confided that
they were suffering from opioid use disorder, I feel confident that they would receive high quality
services from the place where I referred them for treatment.” There was no significant difference
in the proportion of practitioners (63%) and community stakeholders (55%) that agreed or strongly
agreed with the statement (Figure 39).

Figure 39. Distribution of agreement among practitioners (n=145) and community stakeholders (n=98) with
the statement, “If a person came to me and confided that they were suffering from opioid use disorder, I
feel confident that they would receive high quality services from the place where I referred them for
treatment.”
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Among practitioners, there were no significant differences in the proportion that agreed or strongly
agreed with the statement, “If a person came to me and confided that they were suffering from
opioid use disorder, I feel confident that they would receive high quality services from the place
where I referred them for treatment,” by waiver status, rurality, or role type (Figure 40). Among
rural practitioners only, there were no significant differences in the proportion of practitioners that
agreed or strongly agreed with the statement based on waiver status or role type (data not shown).

Figure 40. Distribution of agreement among practitioners with the statement, “If a person came to me and
confided that they were suffering from opioid use disorder, I feel confident that they would receive high
quality services from the place where I referred them for treatment,” stratified by role type (clinicians
n=76 vs. counselors n=69), waiver status (waivered n=28 vs. non-waivered n=18), and rurality (rural n=78 vs.
non-rural n=66).
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There was no significant difference between the proportion of rural (57%) and non-rural (50%)
community stakeholders that agreed or strongly agreed with the statement, “If a person came to
me and confided that they were suffering from opioid use disorder, I feel confident that they would
receive high quality services from the place where I referred them for treatment” (Figure 41).

Figure 41. Distribution of agreement among rural (n=72) and non-rural (n=26) community stakeholders with
the statement, “If a person came to me and confided that they were suffering from opioid use disorder, I
feel confident that they would receive high quality services from the place where I referred them for
treatment.”

Figure 42, Figure 43, and Figure 44 show the distribution of responses among practitioners and
community stakeholders with the statement, “If a person came to me and confided that they were
suffering from opioid addiction, I feel confident that they would receive timely access to services
from the place where I referred them for treatment.” There was no significant difference in the
proportion of practitioners (43%) and community stakeholders (34%) that agreed or strongly agreed
with the statement (Figure 42).

Figure 42. Distribution of agreement among practitioners (n=143) and community stakeholders (n=97) with
the statement, “If a person came to me and confided that they were suffering from opioid addiction, I feel
confident that they would receive timely access to services from the place where I referred them for
treatment.”
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The proportion of rural practitioners (52%) that agreed or strongly agreed with the statement, “If a
person came to me and confided that they were suffering from opioid addiction, I feel confident
that they would receive timely access to services from the place where I referred them for
treatment,” was significantly higher than the proportion of non-rural practitioners (34%; p=0.030)
(Figure 43). The proportion of clinicians (51%) that agreed or strongly agreed with this statement
was significantly higher than the proportion of counselors (34%; p=0.041) (Figure 43). Nearly twothirds of waivered practitioners (64%) agreed or strongly agreed with the statement compared to
39% of non-waivered practitioners, but this difference was not significant (Figure 43). Among rural
practitioners only, the proportion of clinicians (n=37; 64%) that agreed or strongly agreed with the
statement was significantly higher than that of counselors (n=40; 40%; p=0.029). Among rural
practitioners, there was no significant difference in agreement by waiver status (data not shown).

Figure 43. Practitioner agreement with the statement, “If a person came to me and confided that they
were suffering from opioid addiction, I feel confident that they would receive timely access to services
from the place where I referred them for treatment,” stratified by role type (clinicians n=76 vs. counselors
n=67), waiver status (waivered n=28 vs. non-waivered n=18), and rurality (rural n=77 vs. non-rural n=65).
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There was no significant difference in the proportion of rural and non-rural community stakeholders
that agreed or strongly agreed with the statement, “If a person came to me and confided that they
were suffering from opioid addiction, I feel confident that they would receive timely access to
services from the place where I referred them for treatment” (Figure 44).

Figure 44. Distribution of agreement among rural (n=72) and non-rural (n=25) community stakeholders
(n=96) with the statement “If a person came to me and confided that they were suffering from opioid
addiction, I feel confident that they would receive timely access to services from the place where I
referred them for treatment.”

Figure 45, Figure 46, and Figure 47 show the distribution of agreement among practitioners and
community stakeholders with the statement, “Medications (like methadone and buprenorphine)
are the most effective way to treat people with opioid use disorder.” The proportion of
practitioners (65%) that agreed or strongly agreed with the statement was significantly higher than
the proportion of community stakeholders (35%; p<0.0005) (Figure 45). Only 7% of practitioners
disagreed or strongly disagreed with this statement.

Figure 45. Distribution of agreement among practitioners (n=146) and community stakeholders (n=98) with
the statement, “Medications (like methadone and buprenorphine) are the most effective way to treat
people with opioid use disorder.”

The proportion of clinicians (81%) that agreed or strongly agreed with the statement, “Medications
(like methadone and buprenorphine) are the most effective way to treat people with opioid use
disorder,” was significantly higher than that of counselors (48%; p<0.0005) (Figure 46). There were
no significant differences in practitioner agreement by rurality or waiver status.
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Among rural practitioners only, the proportion of clinicians (n=37; 81%) that agreed or strongly
agreed with this statement was significantly higher than the proportion of counselors (n=41; 39%;
p<0.0005). Among rural practitioners only, there was no difference in agreement by waiver status
(data not shown).

Figure 46. Distribution of practitioner agreement with the statement, “Medications (like methadone and
buprenorphine) are the most effective way to treat people with opioid use disorder,” stratified by role
type (clinicians n=77 vs. counselors n=69), waiver status (waivered n=28 vs. non-waivered n=18), and
rurality (rural n=78 vs. non-rural n=67).
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There was no significant difference in the proportion of rural and non-rural community stakeholders
that agreed or strongly agreed with the statement, “Medications (like methadone and
buprenorphine) are the most effective way to treat people with opioid use disorder.” (Figure 47).

Figure 47. Distribution of agreement among rural (n=72) and non-rural (n=26) community stakeholders with
the statement, “Medications (like methadone and buprenorphine) are the most effective way to treat
people with opioid use disorder.”

Figure 48, Figure 49, and Figure 50 show the distribution of agreement among practitioners and
community stakeholders with the statement, “Treatment involving detoxification/abstinence
should be tried before medications (like methadone and buprenorphine).”
There was no significant difference between the proportion of practitioners (17%) and community
stakeholders (27%) that agreed or strongly agreed with the statement, “Treatment involving
detoxification/abstinence should be tried before medications (like methadone and
buprenorphine)” (Figure 48). Notably, 56% of practitioners disagreed with this statement.

Figure 48. Distribution of agreement among practitioners (n=140) and community stakeholders (n=96) with
the statement, “Treatment involving detoxification/abstinence should be tried before medications (like
methadone and buprenorphine).”
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The proportion of non-waivered practitioners (17%) that agreed or strongly agreed with the
statement, “Treatment involving detoxification/abstinence should be tried before medications
(like methadone and buprenorphine)” was significantly higher than that of waivered practitioners
(0%), none of whom agreed with the statement (p=0.038) (Figure 49). There were no significant
differences in the practitioner agreement with the statement by rurality or role type. Among rural
practitioners only, the proportion of counselors that agreed or strongly agreed with the statement
(n=40; 30%) was significantly higher than that of clinicians (n=35; 9%; p=0.021).

Figure 49. Distribution of practitioner agreement with the statement, “Treatment involving
detoxification/abstinence should be tried before medications (like methadone and buprenorphine),”
stratified by role type (clinicians n=73 vs. counselors n=67), waiver status (waivered n=24 vs. non-waivered
n=18), and rurality (rural n=75 vs. non-rural n=64).
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There was no significant difference in the proportion of rural (25%) and non-rural (32%) community
stakeholders that agreed or strongly agreed with the statement, “Treatment involving detoxification/abstinence should be tried before medications (like methadone and buprenorphine)”
(Figure 50).

Figure 50. Distribution of agreement among rural (n=71) and non-rural (n=25) community stakeholders with
the statement, “Treatment involving detoxification/abstinence should be tried before medications (like
methadone and buprenorphine).”

Figure 51, Figure 52, and Figure 53 show the distribution of agreement among practitioners and
community stakeholders with the statement, “Medications given to treat people with opioid use
disorder (specifically methadone and buprenorphine) replace addiction to one kind of drug with
another.”
There was no significant difference between the proportion of practitioners (18%) and community
stakeholders (27%) that agreed or strongly agreed with the statement, “Medications given to treat
people with opioid use disorder (specifically methadone and buprenorphine) replace addiction to
one kind of drug with another” (Figure 51).

Figure 51. Distribution of agreement among practitioners (n=126) and community stakeholders (n=94) to
the statement, “Medications given to treat people with opioid use disorder (specifically methadone and
buprenorphine) replace addiction to one kind of drug with another.”
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There was no significant difference in practitioner agreement with the statement, “Medications
given to treat people with opioid use disorder (specifically methadone and buprenorphine) replace
addiction to one kind of drug with another,” by waiver status, rurality, or role type (Figure 52).
Among rural practitioners only, there was no significant difference in practitioner agreement with
the statement by waiver status or role type (data not shown).

Figure 52. Practitioner agreement with the statement, “Medications given to treat people with opioid use
disorder (specifically methadone and buprenorphine) replace addiction to one kind of drug with another,”
by role type (clinicians n=66 vs. counselors n=60), waiver status (waivered n=21 vs. non-waivered n=16), and
rurality (rural n=71 vs. non-rural n=54).
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There was no significant difference by rurality in community stakeholder agreement with the
statement, “Medications given to treat people with opioid use disorder (specifically methadone
and buprenorphine) replace addiction to one kind of drug with another.” (Figure 53).

Figure 53. Distribution of agreement among rural (n=71) and non-rural (n=23) community stakeholders with
the statement, “Medications given to treat people with opioid use disorder (specifically methadone and
buprenorphine) replace addiction to one kind of drug with another.”

Figure 54 shows the distribution of agreement among all practitioners (n=136) with the statement
“I would prefer to prescribe extended release Vivitrol/Naltrexone instead of extended release
buprenorphine.” Notably, 54% of practitioners neither agreed nor disagreed with the statement,
whereas 24% agreed. Practitioners who agreed listed reasons for their agreement, which included
less chance of medication diversion, medications being harder to abuse, and availability of the
medication. Reasons for Vivitrol preference included it not being an opiate derivative medication,
and perceptions that it is a healthier medication choice.

Figure 54. Distribution of agreement among practitioners (n=136) with the statement, “I would prefer to
prescribe extended release Vivitrol/Naltrexone instead of extended release Buprenorphine.”
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A significantly higher proportion of non-waivered practitioners agreed with the statement, “I would
prefer to prescribe extended release Vivitrol/Naltrexone instead of extended release buprenorphine,” than waivered practitioners (p=0.044) (Figure 55). There was no statistically significant
difference in practitioner agreement by rurality (Figure 55). Among rural practitioners only, there
was no statistically significant difference in practitioner agreement by waiver status (data not
shown).

Figure 55. Distribution of agreement among practitioners the statement, “I would prefer to prescribe
extended release Vivitrol/Naltrexone instead of extended release Buprenorphine,” by waiver status
(waivered n=22 vs. non-waivered n=17), and rurality (rural n=72 vs. non-rural n=63).

COVID-19 Impact
Our survey included questions about the COVID-19 pandemic and its impact on health, substance
use, and treatment access. Throughout this section we use chi-square tests of independence with a
significance threshold of p<0.05 to assess differences between groups.
New Hampshire practitioners (n=142) and community stakeholders (n=96) were asked about their
concern about the health of people in their practice/community in regard to the COVID-19 pandemic
(scale 0–10). Table 16 shows the distribution of these levels of concern among practitioners and
community stakeholders who responded to the question. Levels of concern among practitioners
(mean score=7.6) and community stakeholders (mean score=7.7) were generally high. There was no
significant difference between rural and non-rural practitioners in their concern about the health of
patients in their practice regard to the COVID-19 pandemic. Similarly, there was no significant
difference in between rural and non-rural community stakeholders in their concern about the health
of people in their community regarding the COVID-19 pandemic.
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Non-waivered practitioners’ mean concern level (8.8) was significantly higher than waivered
practitioners’ mean concern level (7.4; p=0.048). This association did not persist when limiting the
analysis to rural practitioners only (data not shown). There was no significant difference in mean
concern level by role type (clinicians vs. counselors) among all practitioners (Table 16) or among rural
practitioners only (data not shown).
Table 16. Practitioner and community stakeholder mean level of concern (scale 0–10) about the health of
people in their practice/community regarding the COVID-19 pandemic.
N

Mean

142
77
64

7.6
7.6
7.5

Waivered practitioners
Non-waivered practitioners

28
16

7.4
8.8

Counselors, case managers, and recovery coaches
Clinicians and pharmacists

67
75

7.3
7.8

96
70
26

7.7
7.6
7.9

All practitioners
Rural practitioners
Non-rural practitioners

All community stakeholders
Rural community stakeholders
Non-rural community stakeholders

Table 17 shows practitioner (n=130) and community stakeholder (n=88) perceptions of substance
use changes during the COVID-19 pandemic. The overwhelming majority of practitioners (87%) and
community stakeholders (88%) reported that substance use had increased since the start of the
COVID-19 pandemic. These proportions were similar across rural and non-rural respondents among
both practitioners and community stakeholders (data not shown).
Table 17. Distribution of practitioner and community stakeholder responses to the question, “How has
substance use changed since the COVID-19 pandemic began?”
Community
Practitioners
Stakeholders
Total
Freq.
Percent
Freq.
Percent
Freq.
Percent
Substance use increased
Substance use stayed same
Substance use decreased
Total*

113
15
2
130

86.9
11.5
1.5
100

77
10
1
88

87.5
11.4
1.1
100

190
25
3
218

87.2
11.5
1.4
100

*Excludes responses of “I don’t know” (practitioner freq.=10, community stakeholder freq.=7) and “Other”
(practitioner freq.=6, community stakeholder freq.=3).
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Table 18 shows practitioner (n=125) and community stakeholder (n=77) perceptions of opioid use
during the COVID-19 pandemic. Most practitioners (79%) and community stakeholders (71%)
reported that opioid use had increased. These proportions were similar across rural and non-rural
respondents (data not shown).

Table 18. Distribution of practitioner and community stakeholder responses to the question, “How has
opioid use changed since the COVID-19 pandemic began?”
Practitioners
Community Stakeholders
Total
Freq.
Percent
Freq.
Percent
Freq. Percent
Opioid use increased
Opioid use stayed same
Opioid use decreased
Total*

99
21
5
125

79.2
16.8
4.0
100

55
20
2
77

71.4
26.0
2.6
100

154
41
7
202

76.2
20.3
3.5
100

*Excludes responses of “I don’t know” (practitioner freq. = 17, community stakeholder freq. = 15) and “Other”
(practitioner freq. = 4, community stakeholder freq.= 4)

Table 19. Distribution of practitioner and community stakeholder responses to the question, “How has
access to opioid treatment changed since the COVID-19 pandemic began?”

Table 19 shows practitioner (n=122) and community stakeholder (n=87) perceptions of changes in
access to MOUD treatment during the COVID-19 pandemic. The majority of practitioners (62%) and
community stakeholders (61%) reported that access to MOUD had decreased since the COVID-19
pandemic began. These proportions were similar across rural and non-rural respondents (data not
shown).

Table 19. Distribution of practitioner and community stakeholder responses to the question, “How has
access to opioid treatment changed since the COVID-19 pandemic began?”
Practitioners
Community Stakeholders
Total

Access to MOUD decreased
Access to MOUD stayed same
Access to MOUD increased

Freq.
75
38
9

Percent
61.5
31.2
7.4

Freq.
53
28
6

Percent
60.9
32.2
6.9

Freq.
128
66
15

Percent
61.2
31.6
7.2

Total*
122
100
87
100
209
100
*Excludes responses of “I don’t know” (practitioner freq.=14, community stakeholder freq.=10) and
“Other” (practitioner freq.=10, community stakeholder freq.=1).
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Figure 56 shows the proportion of practitioners (n=144) that reported taking various measures to
ensure continued treatment for SUD during the COVID-19 pandemic. Most practitioners (83%)
reported using telehealth for individual appointments, while fewer engaged in other measures,
including telehealth for group sessions (32%), changing prescribing patterns (26%), and conducting
appointments outside (21%).

Figure 56. Measures taken by practitioners (n=144) to ensure continued substance use disorder (SUD)
treatment for patients during the COVID-19 pandemic.

PAGE 59

UVMCORA.ORG

NEW HAMPSHIRE: PRACTITIONERS AND STAKEHOLDERS

Figure 57 shows the proportion of rural (n=76) and non-rural (n=67) practitioners that reported
taking various measures to ensure continued treatment for SUD during the COVID-19 pandemic. A
greater proportion of rural practitioners than non-rural practitioners reported conducting
appointments outdoors (rural=28%, non-rural=13%; p=0.037) and utilizing telehealth for group
sessions (rural=45%, non-rural=18%; p=0.001). There were no other statistically significant
differences between rural and non-rural practitioners.

Figure 57. Measures taken by rural (n=76) and non-rural practitioners (n=67) to ensure continued substance
use disorder (SUD) treatment for patients during the COVID-19 pandemic.
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Figure 58 shows the distribution of practitioner responses to the question, “What has your
experience been with changes in substance use disorder treatment services during the coronavirus
pandemic (COVID-19)? What has been working or not working for you?” Practitioners generally
reported that getting paid or reimbursed for telehealth services was working for them (91%). In
contrast, there were several treatment services that practitioners reported were not working. Nearly
two thirds (63%) of practitioners reported that random pill counts were not working, and nearly half
of practitioners (44%) reported issues with patients having sufficient cellphone data or minutes to
attend telehealth appointments. There were no statistically significant differences in processes
identified as working or not working across rural and non-rural practitioners (data not shown).

Figure 58. Distribution of practitioner responses (sample size range: n=68–120) to the question, “What has
your experience been with changes in substance use disorder treatment services during the coronavirus
pandemic (COVID-19)? What has been working or not working for you?”
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Practitioner UVM CORA Resource Requests
Our survey included questions about which UVM CORA resources would be most helpful to
practitioners. Throughout this section we use chi-square tests of independence with a significance
threshold of p<0.05 to assess differences between groups.
Practitioners were asked, “Which of the following resources available through the UVM Center on
Rural Addiction would you like to learn more about for your own clinical practice?” Figure 59 shows
the proportion of practitioners (n=147) that selected various UVM CORA trainings or resources as
“high priority,” and Table 20 provides in-depth descriptions of these resources. The resources most
commonly ranked as “high priority” by practitioners were vulnerable population management (82%),
manualized trainings for co-occurring conditions (75%), and consultation and support from
community "champion" providers (e.g., mentoring, coaching, consultations around complex
patients, medication management; 71%) (Figure 59). There was no significant difference between
the proportion of rural (n=81) and non-rural (n=70) practitioners interested in any UVM CORA
resource (data not shown).

Figure 59. Percent of practitioners (n=147) indicating "high priority" interest in UVM CORA resources.
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Table 20. University of Vermont Center on Rural Addiction (UVM CORA) Resources.
Resource
Description
A. Vulnerable population
management*
B. Manualized trainings for cooccurring conditions*
C. Mentoring from champion
providers*
D. Extended release
buprenorphine medication
and training*
E. Buprenorphine protocols

F. Technical assistance on
treatment adherence

G. New models of care*
H. Screenings/assessments for
treatment needs*
I. Fentanyl testing strips and
intranasal naloxone*
J.

Biochemical monitoring
assistance

K. iPads with apps
L. Practice workflow
consultation

Support with managing and coordinating care for vulnerable
populations (e.g., pregnant patients with SUDs, families, patients with
co-occurring conditions)
Training in manualized treatments for addressing co-occurring
conditions (i.e., smoking cessation, stimulant use, PTSD)
Consultation & support from community "champion" providers (e.g.,
mentoring, coaching, consultations around complex patients,
medication management)
Providing medication & training on extended-release buprenorphine
(e.g., monthly depot formulation) for potential use with patients
Protocols for buprenorphine induction, stabilization, maintenance,
taper, etc.
Technology-assisted hardware & software to support opioid use
treatment adherence in patients (e.g., portable computerized
medication dispensers, IVR system for making automated telephone
calls to patients for clinical monitoring, random call backs, etc.)
Consultations on new models of care for opioid use disorder
treatment (e.g., hub-and-spoke model, buprenorphine initiation in
ED)
Screening/assessments to help identify patients' substance use
treatment needs
Providing fentanyl testing strips; intranasal naloxone (Narcan®) &
materials on its use
Help with biochemical monitoring of recent drug use (e.g., urine
toxicology support, hand-held alcohol breath monitors, hand-held
smoking monitors)
iPads pre-loaded with automated apps on opioid overdose, HIV,
Hepatitis C prevention that can be used by patients while waiting
Consultation or practice workflow or practical implementation opioid
treatment

*Rated as high priority by at least 50% of practitioners who responded to the question (n=147).
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Figure 60 shows practitioner respondents’ preferences regarding how they would like to receive
UVM CORA resources, trainings, and support to serve more patients with SUDs. The most preferred
methods among practitioners were webinars/online trainings (81%) and provider-to-provider
consultations (68%). There were no significant differences in rural (n=77) and non-rural (n=68)
practitioners’ preferences regarding methods for receiving UVM CORA resources, trainings, and
support to serve more patients with SUDs.

Figure 60. Practitioners’ (n=146) preferred methods for receiving University of Vermont Center on Rural
Addiction (UVM CORA) resources and trainings.
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Figure 61 shows practitioner responses to the question, “What resources or services would help
you to become waivered to prescribe buprenorphine?” which was asked only of prescribing
practitioners who did not have a buprenorphine waiver at the time of the survey. Although there
have been changes in federal policy around training requirements for obtaining a buprenorphine
waiver since the time of survey administration,5 the answers to this question remain relevant for
understanding practitioner barriers to treating patients with OUD.
Among these non-waivered practitioner respondents (n=16), two-thirds listed financial support or
incentives (63%), and waiver training on-location at their practices (63%) as resources and services
that would help them obtain a buprenorphine waiver (Figure 61). Although the sample sizes for each
group were small (rural n=8; non-rural n=8), a significantly higher proportion of non-rural
practitioners (63%) selected provider-to-provider consultation or support than rural practitioners
(13%; p=0.039). Additionally, a significantly higher proportion of rural practitioners (75%) selected
ongoing training via webinars than non-rural practitioners (25%; p=0.046). There were no other
significant differences in UVM CORA resources selected by practitioner rurality (data not shown).

Figure 61. Selection of UVM CORA resources in response to the question, "What resources or services
would help you to become waivered to prescribe buprenorphine?" among prescribing practitioners
without buprenorphine waivers (n=16).

5

For more information about current buprenorphine waiver policies, please visit:
https://www.samhsa.gov/medication-assisted-treatment/become-buprenorphine-waivered-practitioner
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Practitioner Ability to Provide Data for Evaluation Efforts
Figure 62 shows the different types of data that practitioners reported being willing and able to share
as part of UVM CORA evaluation efforts. Nearly three-quarters (73%) of practitioners reported that
it would be feasible to share the number of patients treated for OUD. Almost two-thirds (64%)
reported that it would be feasible to share the number of providers at their practice who have
prescribed MOUD. Only one-quarter of practitioners reported that it would be feasible to collect and
share the number of patients offered new or improved SUD interventions.
A significantly higher proportion of non-rural practitioners (n=48; 52%) reported that it was feasible
to collect and share their number and types of SUD treatments, resources, and referrals compared
to rural practitioners n=52; 33%; p=0.050). There were no other significant differences between rural
and non-rural practitioners in the evaluation metrics they identified as being willing and able to share
(data not shown).

Figure 62. Percent of practitioners (n=101) reporting evaluation measures as feasible to collect & share with
the UVM Center on Rural Addiction (UVM CORA). Abbreviations: OUD—opioid use disorder; SUD—
substance use disorder; MOUD—medications for opioid use disorder.
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One of the services that UVM CORA offers is assistance with surveillance and evaluation efforts for
practitioners. Table 21 shows the distribution of practitioner responses (n=106) to the question,
“What support would you most need to be able to collect and share these data with UVM CORA?”
The most-identified support was assistance with data collection systems (41%). There were no
significant differences between rural (n=58) and non-rural (n=47) practitioners in the supports that
they identified.
Table 21. Practitioner supports (single choice) needed to collect and share data with the University of
Vermont Center on Rural Addiction (UVM CORA).

Data collection system
Other
Financial support
Data entry
Help chart audit
Total

Freq.
42
29
18
11
5
105

Percent
40.0
27.6
17.1
10.5
4.8
100
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Most Important Improvement Needed
Practitioners and community stakeholders had varied responses to the question, “What would you
recommend as the SINGLE most important improvement to increase access to opioid use disorder
treatment?”
▪

“Increasing the number of providers in the region that offer appropriate levels of care for
individuals with opioid use disorders.” – Non-rural community stakeholder

▪

“More treatment providers. We have a good Doorway program but not enough places to
refer to.” – Non-rural community stakeholder

▪

“To be timely in response. The window that someone chooses to make this life change can
be small, and if organizations allow too much time between patient contact and response,
that time may pass.” – Rural community stakeholder

▪

“Having more providers available. When patients are ready for help, they need to have that
help in a more timely manner.” – Non-rural practitioner

▪

“Availability of treatment sites in less populated areas.” – Rural practitioner

Share and Learn
Below are highlighted responses to the question, “Is there anything else you would like to share
with us?”
▪

“An individual's treatment plan should depend on the needs of that individual—the state of
NH needs better processes in place to ensure appropriate levels of care are available for
individuals once they've received a clinical assessment. Additionally, programs such as drug
court (and others) need to move away from ‘one approach fits all’ and allow individuals to
utilize the appropriate level of care for them (i.e., not sending everyone through 28-day
programs).” – Non-rural community stakeholder

▪

“Most important improvements are in policy and legislation—buprenorphine should be free
of cost and access not restricted by X-waiver requirements.” – Rural practitioner

▪

“Telehealth needs to stay—it's increased options for our remote patients without
transportation.” – Rural community stakeholder
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Please contact us at cora@uvm.edu with any questions or for more information.

Suggested Reference
University of Vermont Center on Rural Addiction (2022). New Hampshire Baseline Needs Assessment:
Practitioners and Stakeholders. Retrieved from: www.uvmcora.org.

PAGE 69

